Decreased antibody response after severe acute respiratory syndrome coronavirus 2 vaccination in patients with Down syndrom

Bianca M M Streng, Marin Bont, Eveline M Delemarre, Rob S Binnendijk, Gaby Smit, Gerco Den Hartog, Antonia M W Coppus, Esther De Vries, Michel E Weijerman, Regina Lamberts, Gert De Graaf, Fiona R Van Der Klis, Gestur Vidarsson, Neele Rave, Louis J Bont, Joanne G Wildenbeest*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

2 Citations (Scopus)
38 Downloads (Pure)

Abstract

The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.

In this prospective cohort study that included 222 adults with Down syndrome, a significantly lower antibody response was found after SARS-CoV-2 mRNA or vector vaccination compared to healthy controls. After mRNA vaccination, lower antibodies were found with increasing age.

Original languageEnglish
Pages (from-to)673-677
JournalThe Journal of Infectious Diseases
Volume226
Issue number4
DOIs
Publication statusPublished - 2022

Keywords

  • Adult
  • Antibodies, Viral
  • Antibody Formation
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19/prevention & control
  • Down Syndrome
  • Humans
  • Prospective Studies
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccination

Fingerprint

Dive into the research topics of 'Decreased antibody response after severe acute respiratory syndrome coronavirus 2 vaccination in patients with Down syndrom'. Together they form a unique fingerprint.

Cite this